Suppr超能文献

拓宽瓶颈:在大肠杆菌中异源表达、纯化和表征 Ktedonobacter racemifer 最小型 II 聚酮合酶。

Widening the bottleneck: Heterologous expression, purification, and characterization of the Ktedonobacter racemifer minimal type II polyketide synthase in Escherichia coli.

机构信息

Haverford College, Department of Chemistry, Haverford, PA 19041, United States.

Haverford College, Department of Chemistry, Haverford, PA 19041, United States.

出版信息

Bioorg Med Chem. 2020 Oct 15;28(20):115686. doi: 10.1016/j.bmc.2020.115686. Epub 2020 Aug 15.

Abstract

Enzyme assemblies such as type II polyketide synthases (PKSs) produce a wide array of bioactive secondary metabolites. While the molecules produced by type II PKSs have found remarkable clinical success, the biosynthetic prowess of these enzymes has been stymied by 1) the inability to reconstitute the bioactivity of the minimal PKS enzymes in vitro and 2) limited exploration of type II PKSs from diverse phyla. To begin filling this unmet need, we expressed, purified, and characterized the ketosynthase chain length factor (KS-CLF) and acyl carrier protein (ACP) from Ktedonobacter racemifer (Kr). Using E. coli as a heterologous host, we obtained soluble proteins in titers signifying improvements over previous KS-CLF heterologous expression efforts. Characterization of these enzymes reveals that KrACP has self-malonylating activity. Sedimentation velocity analytical ultracentrifugation (SV-AUC) analysis of holo-KrACP and KrKS-CLF indicates that these enzymes do not interact in vitro, suggesting that the acylated state of these proteins might play an important role in facilitating biosynthetically relevant interactions. These results lay important groundwork for optimizing the interaction between KrKS-CLF and KrACP and exploring the biosynthetic potential of other non-actinomycete type II PKSs.

摘要

酶复合物,如 II 型聚酮合酶 (PKSs),可产生多种生物活性的次级代谢产物。虽然 II 型 PKS 产生的分子在临床上取得了显著的成功,但这些酶的生物合成能力受到了以下两个因素的阻碍:1)无法在体外重建最小 PKS 酶的生物活性;2)对来自不同门的 II 型 PKS 的探索有限。为了开始满足这一未满足的需求,我们表达、纯化并表征了 Ktedonobacter racemifer (Kr) 的酮合酶链长因子 (KS-CLF) 和酰基载体蛋白 (ACP)。我们使用大肠杆菌作为异源宿主,获得了可溶蛋白,其产量标志着比以前的 KS-CLF 异源表达努力有了显著提高。这些酶的特性表明,KrACP 具有自我丙二酰化活性。全酶酰基载体蛋白 (holo-KrACP) 和 KrKS-CLF 的沉降速度分析超速离心 (SV-AUC) 分析表明,这些酶在体外不相互作用,这表明这些蛋白的酰化状态可能在促进生物合成相关相互作用方面发挥重要作用。这些结果为优化 KrKS-CLF 和 KrACP 之间的相互作用以及探索其他非放线菌 II 型 PKS 的生物合成潜力奠定了重要基础。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验